通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000766 通化金马

已收盘 04-17 15:00:00

{"stockData":{"symbol":"000766","market":"SZ","secType":"STK","nameCN":"通化金马","latestPrice":23.65,"timestamp":1776409383000,"preClose":22.93,"halted":0,"volume":22787905,"delay":0,"changeRate":0.0314,"floatShares":966000000,"shares":966000000,"eps":0.0595,"marketStatus":"已收盘","change":0.72,"latestTime":"04-17 15:00:00","open":22.71,"high":23.8,"low":22.71,"amount":534000000,"amplitude":0.0475,"askPrice":23.65,"askSize":328,"bidPrice":23.64,"bidSize":390,"shortable":0,"etf":0,"ttmEps":0.0595,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":22.93,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":25.22,"lowLimit":20.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":966494707,"isCdr":false,"pbRate":9.63,"roa":"--","peRate":397.478992,"roe":"1.1%","epsLYR":0.06,"committee":-0.293514,"marketValue":22858000000,"turnoverRate":0.0236,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-20。","floatMarketCap":22846000000},"requestUrl":"/m/hq/s/000766/tweets","defaultTab":"tweets","newsList":[{"id":"2627407570","title":"通化金马（000766）披露独立董事任期届满辞职公告，4月15日股价上涨1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407570","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407570?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:06","pubTimestamp":1776243969,"startTime":"0","endTime":"0","summary":"通化金马药业集团股份有限公司于近日披露《关于独立董事任期届满的公告》。公告显示，2026年4月14日，公司董事会收到独立董事吕桂霞女士的书面辞职报告。吕桂霞女士自2020年4月15日起担任公司独立董事，因连续任职已达6年，申请辞去独立董事、审计委员会主任委员、薪酬与考核委员会委员职务。在新任独立董事就任前，吕桂霞女士将继续履行职责。吕桂霞女士不持有公司股份，与公司及董事会无意见分歧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","BK0239","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625594119","title":"通化金马：目前公司尚未筹划此事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2625594119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625594119?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:51","pubTimestamp":1775652669,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)04月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司近期再策划出售公司及变更实际控制人？通化金马回复：您好。目前公司尚未筹划此事项。有关公司的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800036376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0060","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625915200","title":"通化金马：琥珀八氢氨吖啶片目前已完成综合审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625915200","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625915200?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:51","pubTimestamp":1775634665,"startTime":"0","endTime":"0","summary":"投资者提问：琥珀八氢氨吖啶片这款新药从受理到现在，已经审了 19个月而法定审评时限：200个工作日截止目前还没有任何获批的消息。是不是审批异常了，或者有其它重大违规性问题了呢通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片目前已完成综合审评工作，并已按要求提供各专业研究资料，当前药审中心正在按工作程序在规定的审批时限内开展最后审评工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800021000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0239","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501511","title":"通化金马：琥珀八氢氨吖啶片已完成综合审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624501511?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:51","pubTimestamp":1775134286,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问新药审批进展如何通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片目前已完成综合审评工作，并已按要求提供各专业研究资料，当前药审中心正在按工作程序在规定的审批时限内开展最后审评工作。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200039543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","000766","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898502","title":"股市必读：通化金马（000766）今年截至3月26日累计跌幅已超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898502","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622898502?lang=zh_cn&edition=full","pubTime":"2026-03-27 01:57","pubTimestamp":1774547862,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，通化金马报收于19.24元，下跌0.52%，换手率1.23%，成交量11.89万手，成交额2.3亿元。交易信息汇总股价提醒3月26日通化金马收盘报19.24元，跌0.52%，当日成交1188.86万元。根据收盘数据统计，该股当年累计跌幅30.67%。前10个交易日资金流向情况：主力资金累计净流出4297.24万元，股价累计下跌9.5%；融资余额累计减少8849.55万元，融券余量累计增加1.61万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700003921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621704773","title":"通化金马：公司正积极推进新药商业化相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2621704773","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621704773?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:00","pubTimestamp":1774274400,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n　　证券日报网讯 3月23日，通化金马在互动平台回答投资者提问时表示，公司正积极推进新药商业化相关工作。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-23/doc-inhryxfq2276100.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-23/doc-inhryxfq2276100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","000766","BK0060","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621774459","title":"通化金马：3月23日董事长张玉富增持股份合计52.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774459","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621774459?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:01","pubTimestamp":1774260073,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月23日市场公开信息、上市公司公告及交易所披露数据整理，通化金马最新董监高及相关人员股份变动情况：2026年3月23日公司董事长,总经理张玉富共增持公司股份52.55万股，占公司总股本为0.0544%。通化金马近半年内的董监高及核心技术人员增减持详情如下：通化金马的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出2133.28万，融资余额减少；融券净流入2.08万，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300028543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","000766","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620220420","title":"股市必读：通化金马（000766）今年截至3月19日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620220420","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620220420?lang=zh_cn&edition=full","pubTime":"2026-03-20 01:21","pubTimestamp":1773940872,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，通化金马报收于20.35元，下跌4.05%，换手率1.92%，成交量18.54万手，成交额3.81亿元。交易信息汇总股价提醒3月19日通化金马收盘报20.35元，跌4.05%，当日成交1854.39万元。该股当年累计跌幅26.46%。前10个交易日主力资金累计净流入7301.97万元，股价累计下跌4.27%；融资余额累计减少4226.34万元，融券余量累计增加1.61万股。资金流向3月19日主力资金净流入1879.53万元；游资资金净流出1480.48万元；散户资金净流出399.05万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000001378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","BK0239","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616481923","title":"通化金马(000766.SZ)董事长兼总经理张玉富拟斥1000万元至2000万元实施增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2616481923","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616481923?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:29","pubTimestamp":1772530147,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化金马(000766.SZ)公告董事长兼总经理张玉富先生拟自本公告披露之日起6个月内增持公司股份，计划增持金额不低于1000万元(含)且不超过2000万元(含)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"通化金马(000766.SZ)董事长兼总经理张玉富拟斥1000万元至2000万元实施增持","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0239","BK0060","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614502795","title":"股市必读：通化金马（000766）2月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614502795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614502795?lang=zh_cn&edition=full","pubTime":"2026-02-27 02:18","pubTimestamp":1772129892,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，通化金马报收于23.36元，下跌1.56%，换手率1.4%，成交量13.52万手，成交额3.16亿元。董秘最新回复投资者： 公司二级市场近日都是大单交易，是利益输送还是真实交易？当日关注点来自交易信息汇总：2月26日主力资金净流入173.97万元，游资积极介入，散户资金呈净流出态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700001250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","000766","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614407800","title":"通化金马：2025年度经营业绩将在2025年度报告中披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2614407800","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614407800?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:36","pubTimestamp":1772112960,"startTime":"0","endTime":"0","summary":"证券日报网讯 2月26日，通化金马在互动平台回答投资者提问时表示，公司2025年度经营业绩将在2025年度报告中披露，请投资者关注公司公告。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-26/doc-inhpefhe4273705.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-26/doc-inhpefhe4273705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","BK0077","BK0239","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614041127","title":"通化金马：目前公司生产经营及管理情况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614041127?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:52","pubTimestamp":1772110369,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司内部管理是不是很混乱，服务账号修改了，官方网站内容还是旧的？通化金马回复：您好，目前公司生产经营及管理情况正常，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600035429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","000766","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607584058","title":"股市必读：通化金马（000766）1月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607584058","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607584058?lang=zh_cn&edition=full","pubTime":"2026-01-30 02:43","pubTimestamp":1769712189,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，通化金马报收于26.6元，上涨2.23%，换手率1.91%，成交量18.48万手，成交额4.86亿元。董秘最新回复投资者： 新药获批前，公司会进行所谓二级市场黄金坑的布局吗董秘： 您好，公司严格遵守相关法律法规开展经营活动。交易信息汇总资金流向1月29日主力资金净流入573.75万元；游资资金净流出371.39万元；散户资金净流出202.36万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000001557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000766","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603719205","title":"通化金马：琥珀八氢氨吖啶片进入最后审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2603719205","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603719205?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:48","pubTimestamp":1768276087,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘董高管，新年伊始恭喜贵司创新药审评又进一步，那么接下来到那个环节了通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作并已按要求提供各专业研究资料，进入最后审评环节，各项工作进展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300016888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","000766","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601036490","title":"通化金马：新药已完成综合审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601036490?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:52","pubTimestamp":1767876750,"startTime":"0","endTime":"0","summary":"按照公司之前公告，12月12日机构调研公司的问答记录显示，公司新药当前已经处于综合审评阶段，并且按照CDE规定完成了临床、统计和药学方面的专家综合审评会议，公司完成了上市申请的各项工作。通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各项工作进展正常。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800037007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601038698","title":"通化金马：琥珀八氢氨吖啶片进入最后审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2601038698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601038698?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:51","pubTimestamp":1767790270,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：公司新药进展如何了？通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各项工作进展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700036824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","000766","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595719300","title":"股市必读：通化金马（000766）12月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595719300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595719300?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:59","pubTimestamp":1767113948,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，通化金马报收于27.39元，下跌1.3%，换手率1.25%，成交量12.08万手，成交额3.33亿元。董秘最新回复投资者： 请问新药的审批到什么程度了？有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。交易信息汇总资金流向12月30日主力资金净流出4669.53万元；游资资金净流入1477.83万元；散户资金净流入3191.71万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100000925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595792752","title":"通化金马：新药进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792752","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595792752?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:53","pubTimestamp":1767099187,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问新药的审批到什么程度了？按照规定还需要多长时间？通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000040903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","000766","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591907984","title":"通化金马：琥珀八氢氨吖啶片进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2591907984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591907984?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:51","pubTimestamp":1765889469,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马12月15日在投资者关系平台上答复投资者关心的问题。那么想请问董秘，金马药业目前在审的一类新药琥珀八氢氨吖啶片，是否收到CDE的发补通知？烦请董秘正面回复，毕竟这个问题的答复投资者，并非信披违规。通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600038053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0239","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590151355","title":"通化金马：琥珀八氢氨吖啶片进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2590151355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590151355?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457318,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘 ，最近新药审核进度怎么样了有传说和常山药业一样需要发补  以及贵司张董讲指日可待 这个时间点为什么不和中小股东多沟通下通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000766","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776501719135,"stockEarnings":[{"period":"1week","weight":0.1235},{"period":"1month","weight":0.115},{"period":"3month","weight":-0.1042},{"period":"6month","weight":-0.0634},{"period":"1year","weight":0.3175},{"period":"ytd","weight":-0.1397}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0123},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.2351},{"period":"ytd","weight":0.0208}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化金马药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38232人(较上一季度减少3.20%)","perCapita":"25266股","listingDate":"1997-04-30","address":"吉林省通化市二道江区金马路999号","registeredCapital":"96649万元","survey":"　　通化金马药业集团股份有限公司的主营业务是医药产品的研发、生产与销售。公司的主要产品是复方嗜酸乳杆菌片、乳酸亚铁口服液、风湿祛痛胶囊、清肝健脾口服液、芩石利咽口服液等。公司2019年公司被评定为高新技术企业，荣获“中华民族医药百强品牌企业”、2015年度最具资本力企业奖、2017创新中国十大发展潜力企业、“2022-2023年度中国医药制造业百强”、2023年度中国化药企业TOP100等称号。","listedPrice":7.23},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化金马(000766)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化金马,000766,通化金马股票,通化金马股票老虎,通化金马股票老虎国际,通化金马行情,通化金马股票行情,通化金马股价,通化金马股市,通化金马股票价格,通化金马股票交易,通化金马股票购买,通化金马股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化金马(000766)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}